AI Agentic Workflow for Automated eCTD Technical Validation Pre-Submission

Manual validation is error-prone and occurs too late in the cycle, risking outright rejection or major delays. A custom agentic workflow performs continuous, rule-based validation against the latest FDA eCTD specifications, ICH M8, and EMA technical requirements. This shifts quality assurance left, catching broken hyperlinks, incorrect metadata, and non-compliant file structures weeks before submission, transforming validation from a reactive cost center into a proactive safeguard that protects millions in development investment.

The traditional 'validation sprint' creates a critical-path bottleneck, consuming 20-30 person-days of highly specialized labor. An automated workflow orchestrates parallel validation agents that run on-demand or on a schedule against the publishing workspace. This eliminates the sequential manual queue, allowing teams to lock the submission package faster and with higher confidence. The time savings directly translate to earlier filing dates, which can equate to months of commercial revenue for blockbuster drugs.

Manual checks lack a systematic audit trail, creating compliance risk during inspections. A custom implementation logs every validation rule execution, result, and corrective action in an immutable ledger. This generates a complete, defensible record of technical due diligence, demonstrating ALCOA+ principles for data integrity. The system can automatically compile evidence packs for audits, turning a chaotic process into a governed, repeatable operating model that strengthens regulatory posture.

Validation cannot exist in a silo. The architecture connects directly to publishing tools (e.g., DocuBridge, Liquent) and Regulatory Information Management (RIM) systems like Veeva Vault RIM via APIs. Agents are triggered by document state changes, run validations in the native publishing environment, and post results and health scores back to the RIM. This creates a closed-loop system where validation is a native step in the submission assembly workflow, not a disconnected, post-hoc activity.

Managing technical rules for the FDA, EMA, PMDA, and other health authorities manually is unsustainable. The workflow uses agentic orchestration (e.g., LangGraph) to manage jurisdiction-specific rule sets. A 'Regional Compliance Agent' applies the correct technical specifications based on the submission target, ensuring each package is validated against its precise requirements. This allows a single team to manage validation for concurrent global filings without linearly increasing headcount or error rates.

A list of 10,000 validation errors is paralyzing. The system uses LLM-based analysis to cluster, prioritize, and explain failures, grouping related issues (e.g., all broken links in Module 5) and suggesting root causes. It generates actionable reports for document authors and publishers, routing specific fixes to the right teams. This transforms validation output from noise into a clear correction plan, dramatically accelerating the remediation cycle and improving team productivity.

This agent performs a deep crawl of the submission package, validating the eCTD backbone file (index.xml), verifying all internal and external hyperlinks resolve, and checking that the file/folder hierarchy complies with the required regional structure (e.g., NDA vs. MAA). It flags broken links, missing bookmarks, and incorrect sequence numbers, which are common causes of technical rejection.

Operating at the file level, this agent validates technical attributes against health authority specs. It checks PDF versioning, embedded fonts, security settings, and file naming conventions. It also extracts and validates document-level metadata (e.g., document type, sequence number, related documents) against the eCTD XML, ensuring the submission package is machine-readable for agency systems.

This agent performs semantic validation across the submission. Using RAG over the document corpus, it identifies discrepancies between data in tables, figures, and narratives (e.g., a p-value in a CSR summary that doesn't match the statistical output). It flags inconsistencies in patient numbers, dose levels, and efficacy endpoints across Module 2 summaries and Module 5 study reports.

This agent encodes and executes hundreds of explicit technical rules from FDA Technical Rejection Criteria, EMA Validation Criteria, and ICH eCTD specifications. It checks for issues like non-compliant file sizes, incorrect PDF compression, missing leaf titles, and invalid XML schema. Rules are maintained as versioned code, allowing for rapid updates as agency guidance changes.

The central orchestrator (built on LangGraph or similar) sequences agent execution, manages state, and handles exceptions. It ingests the submission package from a source like Veeva Vault, dispatches tasks to specialized agents, aggregates findings, and generates an actionable validation report. This report categorizes issues by severity (Critical, Major, Minor) and links directly to the problematic files for rapid correction by the publishing team.

This component manages the bidirectional flow between the validation engine and enterprise systems. It pulls draft documents from the Document Management System (e.g., Veeva, Documentum), pushes validation reports and status back into submission trackers (e.g., Veeva RIM), and, upon final approval, triggers the automated publishing workflow in tools like Liquent Publisher or Lorenz eValidator to generate the final, submission-ready eCTD package.

This team defines the validation rulebook and owns the submission timeline. They provide the business case, specifying which technical failures (e.g., broken hyperlinks, non-compliant file naming) cause the most delays and rejection risk. Their sign-off is required on the validation rule set and exception routing logic before the system goes live. Alignment ensures the automation directly targets the 20-30% of validation errors that typically trigger last-minute, high-stress scrambles.

This group manages the source documents in systems like Veeva Vault or OpenText Documentum. They are critical for integration, providing APIs or access patterns for the validation agents to scan draft packages. Their involvement ensures the workflow pulls from the correct document versions and writes validation reports back into the document management workflow, creating a closed-loop correction process.

This team architects the production environment. They are responsible for deploying the agentic orchestration layer (e.g., using LangGraph), managing the pipeline that ingests submission bundles, and ensuring scalable compute for validation runs. They implement the monitoring, logging, and alerting needed for operational health and audit trails. Their buy-in is essential for moving from a proof-of-concept to a system that runs unattended during critical submission windows.

This stakeholder group validates the validator. They must approve the automated workflow's logic for being equivalent to—or more rigorous than—manual checks. They define the requirements for a defensible audit trail, including how the system logs which rule was applied, what data was checked, and the rationale for any flagged issues. Their early involvement prevents rework and ensures the system supports inspection readiness.

As the primary users and beneficiaries, this group receives the actionable validation reports. Their workflow integration is key: the system must flag specific documents and errors (e.g., 'Section 4.2: Reference to Study XYZ-123 is missing from bibliography') within their authoring tools. Alignment ensures the feedback is contextual and reduces mean-time-to-correction, turning a generic error list into directed, efficient rework.

This group funds the build and measures ROI. They care about the workflow's impact on submission cycle time and first-pass acceptance rates. Alignment involves defining success metrics upfront (e.g., reduction in technical deficiency letters, hours saved per submission) and establishing governance for scaling the pilot from one therapeutic area to the entire portfolio. Their sponsorship is necessary to overcome organizational inertia.